ELISA, Bioactivity: FACS, Functional assay, Research in vivo
同种型
half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3
表达系统
Mammalian cells
靶标
Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
内毒素水平
< 10 EU/mg
纯度
>95% purity as determined by SDS-PAGE.
纯化方式
Protein A/G purified from cell culture supernatant.
Accession号
Q15116 & P16410
状态
Liquid
保存溶液
0.01M PBS pH 7.4
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
别名
Bispecific, XmAb-20717, XMAB20717, 2329669-72-7
背景
Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody. • Cancer immunotherapy using checkpoint blockade., PMID:29567705 • The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870 • Immune-related adverse events of checkpoint inhibitors., PMID:32382051 • Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845 • Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113 • Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885 • Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160 • Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858 • Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360 • Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704
Note
For research use only. Not suitable for clinical or therapeutic use.
